Findings on oral drug to be presented at San Antonio Breast Cancer Symposium
<p>Elacestrant may improve care of metastatic ER+/HER2- tumors Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Nov. 30, 2022) — Phase III results of EMERALD, a clinical trial evaluating a novel oral drug therapy for metastatic ER-positive/HER2-negative (ER+/HER2-) breast cancer, will be presented Thursday, Dec. 8, at the San Antonio Breast Cancer Symposium (SABCS). Virginia Kaklamani, MD, […]</p>